Psychosis Clinical Trials

87 recruiting

Psychosis Trials at a Glance

125 actively recruiting trials for psychosis are listed on ClinicalTrialsFinder across 6 cities in 47 countries. The largest study group is Not Applicable with 65 trials, with the heaviest enrollment activity in Miami, Montreal, and Houston. Lead sponsors running psychosis studies include Pakistan Institute of Living and Learning, Douglas Mental Health University Institute, and Northwell Health.

Browse psychosis trials by phase

Treatments under study

About Psychosis Clinical Trials

Looking for clinical trials for Psychosis? There are currently 87 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Psychosis trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Psychosis clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 125 trials

Recruiting
Phase 3

A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)

Psychosis Associated With Alzheimer's Disease
Karuna Therapeutics, Inc., a Bristol Myers Squibb company500 enrolled154 locationsNCT06126224
Recruiting
Phase 4

Examining the Effects of Estradiol on Neural and Molecular Response to Reward

DepressionAnhedoniaPsychosis
University of North Carolina, Chapel Hill103 enrolled1 locationNCT05282277
Recruiting
Phase 3

A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)

Psychosis Associated With Alzheimer's Disease
Karuna Therapeutics, Inc., a Bristol Myers Squibb company410 enrolled116 locationsNCT05511363
Recruiting
Not Applicable

French Validation of Schizophrenia Proneness Instrument- Child Youth

Clinical High Risk for Psychosis (CHR)
Centre Psychothérapique de Nancy52 enrolled3 locationsNCT06649552
Recruiting
Phase 3

Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)

Psychosis Associated With Alzheimer's Disease
Karuna Therapeutics, Inc., a Bristol Myers Squibb company800 enrolled416 locationsNCT05980949
Recruiting
Phase 2

Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia Psychosis

Lewy Body Dementia Psychosis
ACADIA Pharmaceuticals Inc.180 enrolled54 locationsNCT07029581
Recruiting
Phase 3

A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5)

Alzheimer DiseasePsychosis
Bristol-Myers Squibb325 enrolled20 locationsNCT06947941
Recruiting
Phase 3

Efficiency of a Composite Personalised Care on Functional Outcome in Early Psychosis

Psychosis
Centre Hospitalier St Anne500 enrolled13 locationsNCT05796401
Recruiting
Phase 2Phase 3

ACP-204 in Adults With Alzheimer's Disease Psychosis

Alzheimer's Disease Psychosis
ACADIA Pharmaceuticals Inc.1,074 enrolled145 locationsNCT06159673
Recruiting
Phase 2

An Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease Psychosis

Psychosis Associated With Alzheimer's Disease
MapLight Therapeutics210 enrolled3 locationsNCT07459660
Recruiting
Not Applicable

Culturally Adapted Cognitive Behavior Therapy for Individuals At Risk of First Episode Psychosis

Individuals at Risk of First Episode Psychosis
Pakistan Institute of Living and Learning90 enrolled2 locationsNCT07188597
Recruiting

Tau Networks in Psychotic Alzheimer's Disease

Alzheimer DiseaseAlzheimer Disease With DelusionsAlzheimer Disease With Psychosis
Northwell Health91 enrolled1 locationNCT05847192
Recruiting
Phase 1Phase 2

A Study Exploring Changes in a Variety of Biomarkers Following Dosing With MT1988 in Participants at Clinical High Risk for Psychosis

Clinical High Risk for Psychosis (CHR)
Monument Therapeutics Limited150 enrolled15 locationsNCT07226895
Recruiting
Not Applicable

Effects of Action-Based Cognitive Remediation on Substance Misuse in Early Phase Psychosis

Alcohol Use DisorderPsychosisCannabis Use Disorder
Nova Scotia Health Authority50 enrolled2 locationsNCT07056894
Recruiting
Phase 4

Cannabis Potency Effects on Brain White Matter in Early Phase Psychosis

Cannabis UsePsychosis
Nova Scotia Health Authority24 enrolled2 locationsNCT07001878
Recruiting
Phase 1Phase 2

Ocrelizumab for Psychosis by Autoimmunity

SchizophreniaSchizo-Affective Type of Psychosis
The Methodist Hospital Research Institute40 enrolled1 locationNCT03971487
Recruiting

Cerebellum-based Imaging Neural Markers for Antipsychotic Response

Psychosis; Acute
Northwell Health120 enrolled1 locationNCT07483294
Recruiting

Immune Mechanisms of Antipsychotic Treatment Response

Psychosis
King's College London500 enrolled1 locationNCT06687694
Recruiting
Not Applicable

Study of Language Disorders and Interactions Between Mnesic Capabilities and Semantic Competencies in Patients With Psychosis

SchizophreniaPsychosisLanguage Disorders+1 more
Centre Psychothérapique de Nancy90 enrolled1 locationNCT06036316
Recruiting
Not Applicable

Experience of UHR and PEP Individuals During Mindfulness: a Qualitative Phenomenological Study

Clinical High Risk for Psychosis (CHR)
Centre Psychothérapique de Nancy20 enrolled2 locationsNCT07499934